Literature DB >> 32507360

Delirium, sleep, COVID-19 and melatonin.

Viroj Wiwanitkit1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32507360      PMCID: PMC7255123          DOI: 10.1016/j.sleep.2020.05.028

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


× No keyword cloud information.
Dear Editor, the recent article “Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients?” is quite noteworthy [1]. Zambrelli et al., mentioned that “Melatonin's safety in doses up to 10 mg has been shown to be very high in ICU patients and should be used in the prevention and treatment of sleep disturbances and delirium in COVID–19.” [1]. The effect of melatonin on novel coronavirus (COVID-19) infection is a significant issue. In brief, melatonin is effective for reducing anxiety and useful for controlling insomnia. Some recent reports mention the benefit of melatonin in management of COVID-19 [2,3]. Melatonin can help decrease lung fibrosis, which is a significant complication of COVID-19 [2,3]. Therefore, it is recommended that melatonin should be used in any COVID-19 cases regardless of delirium or sleep disturbance.
  2 in total

1.  Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study.

Authors:  Carolina Bologna; Pasquale Madonna; Eduardo Pone
Journal:  J Clin Med       Date:  2021-12-14       Impact factor: 4.241

2.  Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19.

Authors:  Chandrashekhar Kocherlakota; Banda Nagaraju; Narala Arjun; Akula Srinath; Kumar S D Kothapalli; J Thomas Brenna
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2022-03-30       Impact factor: 3.015

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.